RESEARCH ARTICLE

Insights into antitrypanosomal drug mode-of-action from cytology-based profiling

James A. Thomas¹, Nicola Baker², Sebastian Hutchinson³, Caia Dominicus⁴, Anna Trenaman⁵, Lucy Glover³, Sam Alsford¹, David Horn⁵*¹

¹ London School of Hygiene & Tropical Medicine, Keppel Street, London, United Kingdom, ² The Centre for Immunology and Infection, University of York, Heslington, York, United Kingdom, ³ Institut Pasteur, Paris, France, ⁴ The Francis Crick Institute, London, United Kingdom, ⁵ Wellcome Trust Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee, United Kingdom

* d.horn@dundee.ac.uk

Abstract

Chemotherapy continues to have a major impact on reducing the burden of disease caused by trypanosomatids. Unfortunately though, the mode-of-action (MoA) of antitrypanosomal drugs typically remains unclear or only partially characterised. This is the case for four of five current drugs used to treat Human African Trypanosomiasis (HAT); eflornithine is a specific inhibitor of ornithine decarboxylase. Here, we used a panel of T. brucei cellular assays to probe the MoA of the current HAT drugs. The assays included DNA-staining followed by microscopy and quantitative image analysis, or flow cytometry; terminal dUTP nick end labelling to monitor mitochondrial (kinetoplast) DNA replication; antibody-based detection of sites of nuclear DNA damage; and fluorescent dye-staining of mitochondria or lysosomes. We found that melarsoprol inhibited mitosis; nifurtimox reduced mitochondrial protein abundance; pentamidine triggered progressive loss of kinetoplast DNA and disruption of mitochondrial membrane potential; and suramin inhibited cytokinesis. Thus, current antitrypanosomal drugs perturb distinct and specific cellular compartments, structures or cell cycle phases. Further exploiting the findings, we show that putative mitogen-activated protein-kinases contribute to the melarsoprol-induced mitotic defect, reminiscent of the mitotic arrest associated signalling cascade triggered by arsenicals in mammalian cells, used to treat leukaemia. Thus, cytology-based profiling can rapidly yield novel insight into antitrypanosomal drug MoA.

Author summary

African trypanosomes cause devastating and lethal diseases in humans and livestock. These parasites are transmitted among mammals by tsetse flies and circulate and grow in blood and tissue fluids. There are several drugs available to treat patients but, despite their use for many decades, we know relatively little about how they work. We reasoned that exposure of trypanosomes to each drug, followed by microscopic examination of cellular structures, would reveal the major cellular compartments, structures or growth phases affected. For example, we examined two major DNA structures, and cellular
compartments known as mitochondria. We found that two drugs thought to act in mitochondria did indeed disrupt this compartment, but in completely different ways. Another drug stopped cell growth at a specific point in the cycle. An arsenic-based drug, related to anti-leukaemia drugs, perturbed the nuclear DNA division cycle, indicating that arsenicals may kill parasites and cancer cells by similar mechanisms. Thus, the ‘chemical-biology’ profiles we observe illuminate distinct killing mechanisms. A similar approach can now be used to assess new drugs, and the insights may help to develop improved anti-parasite therapies.

Introduction

Chemotherapy is central to the control of the neglected tropical diseases caused by African trypanosomes (Trypanosoma brucei spp), South American trypanosomes (Trypanosoma cruzi) and Leishmania spp; the related kinetoplastid parasites [1]. The current drugs suffer problems with complex administration, efficacy, toxicity and resistance [2]. There are a small number of drugs in clinical trials for these diseases but there remains a desperate need for new and improved drugs. An understanding of drug mode-of-action (MoA) would aid the development of these new drugs, but our knowledge of how the current antitrypanosomals work is lacking [1]. This has also been the case for drugs currently in clinical trials and for other promising compounds that emerged from phenotypic cell-based screening campaigns. These gaps in knowledge will only become more acute given the current trend of phenotypic screening and the typically high attrition rate during the development of compounds that emerge from target-based screening [1].

In the case of Human African Trypanosomiasis (HAT), there are five current drugs, and two in clinical trials [1]. The disease progresses from stage 1 to stage 2, when parasites invade the central nervous system, which is typically lethal without treatment. The current drugs are eflornithine, melarsoprol, nifurtimox, pentamidine and suramin. Nifurtimox and eflornithine were introduced most recently and are used in combination to treat stage 2 disease in West Africa [3]; eflornithine, however, is particularly challenging to administer. Melarsoprol use has been largely phased out, as it is highly toxic [4]. Resistance to melarsoprol, due to the disruption of a parasite aquaglyceroporin [5,6,7], is also now widespread, but this drug remains the only available treatment for stage 2 disease in East Africa; the parasite sub-species found in this region is not susceptible to eflornithine [8]. Pentamidine and suramin are used to treat stage 1 disease in West and East Africa, respectively. The new orally active drugs in clinical trials are acoziborole / SCYX-7158 [9] and fexinidazole [10].

With the exception of eflornithine and acoziborole, the mechanisms of action for the antitrypanosomal drugs above are not understood in any detail. Eflornithine enters trypanosomes via the amino-acid transporter AAT6 [11] and inhibits ornithine decarboxylase [12] and, only recently, acoziborole was shown to target an mRNA maturation factor known as CPSF3 [13]. Almost all antitrypanosomal drugs emerged based on an ability to selectively target trypanosomes or to reduce parasite viability in cell culture or in animal models. Rather than differences between host and parasite intracellular targets, the selective efficacy of suramin, melarsoprol and pentamidine is at least partly due to trypanosome-specific uptake mechanisms [14]. Suramin enters trypanosomes via an endocytic pathway involving a bloodstream stage-specific invariant surface glycoprotein ISG75 [14], and variant surface glycoprotein [15]. The action of suramin is enhanced by the import of ornithine, via an amino acid transporter [16], and its metabolism by ornithine decarboxylase, such that eflornithine is antagonistic [14].
Suramin inhibits pyruvate kinase \textit{in vitro} but the drug may also occupy ADP/ATP binding sites in other enzymes [17], none of which have been validated as targets \textit{in vivo}. Melarsoprol is an arsenical drug that enters trypanosomes via an adenosine transporter [18] and an aquaglyceroporin, AQP2 [5], acting primarily by forming a stable adduct, known as Mel T, with the antioxidant, trypanothione [19]. Pentamidine, like melarsoprol, enters trypanosomes via AQP2 [5]. Indeed, pentamidine inhibits the glycerol permeability of AQP2 [20] but this particular activity has little impact on parasite viability. Rather, this DNA-binding drug [21] becomes highly concentrated in the cell and collapses trypanosome mitochondrial membrane potential [22]. Pentamidine remains a low nanomolar antitrypanosomal agent against parasites lacking mitochondrial (kinetoplast) DNA, however, which display only 2.5-fold resistance [23, 24]. Nifurtimox and fexinidazole are both nitro pro-drugs that are activated by a putative ubiquinone nitroreductase (NTR) located in parasite mitochondria [14, 25, 26], but it is unknown whether these drugs kill parasites primarily by disrupting mitochondrial functions or whether the toxic metabolites access targets outside the mitochondria.

Cytology-based profiling can facilitate antibiotic discovery efforts [27] and a selection of cellular assays have been previously applied to antitrypanosomal compounds [28]; but this previous study examined only one of the current HAT compounds (pentamidine) and employed only two of the assays described below. We now report cytology-based profiling for \textit{T. brucei} to probe the MoA of all five antitrypanosomals used in patients. We describe a panel of assays that assess cell cycle progression, nuclear and mitochondrial DNA content, mitochondrial DNA replication, nuclear DNA damage, mitochondrial membrane potential, and lysosome structure and function. Using these assays, we show that each drug tested induces specific and distinct cellular perturbations, yielding novel insight into the MoA of the antitrypanosomal agents. Follow-up studies revealed a melarsoprol-induced mitotic defect that is dependent upon a specific set of kinases.

**Results**

\textit{T. brucei} growth profiles during exposure to antitrypanosomal drugs

The potency of the antitrypanosomal drugs used in the clinic varies widely. The 50% effective growth inhibitory concentration (EC\textsubscript{50}) determined against bloodstream-form \textit{T. brucei} in culture is in the low nM range for pentamidine (2.5 nM), suramin (27 nM) and melarsoprol (7 nM) but is in the low \textmu M range for eflornithine (15 \textmu M) and nifurtimox (2.6 \textmu M); a 6,000-fold differential between the most potent (pentamidine) and least potent (eflornithine). It is important to note that, since EC\textsubscript{50} values are typically determined over three to four days, they may fail to reflect the rate at which growth is inhibited or whether the compound is cytocidal or cytostatic at a particular concentration.

We examined the growth profiles of bloodstream-form trypanosomes treated with each of the five clinical antitrypanosomal drugs at 1 x EC\textsubscript{50} and 5 x EC\textsubscript{50}; see Materials and methods. All drugs had a relatively moderate impact on growth at 1 x EC\textsubscript{50}, as expected (Fig 1). In contrast, growth at 5 x EC\textsubscript{50} revealed a clear difference between eflornithine, which is known to be cytostatic [29], and the other drugs, which were all demonstrably cytocidal over four days (Fig 1). We selected 5 x EC\textsubscript{50} exposure for 24 hours for subsequent assays. These concentrations and this time-point were selected to achieve a balance between allowing robust primary phenotypes to develop but to minimise the emergence of secondary effects associated with loss of viability.

Our first cellular assay was a simple examination of each of the five populations of drug-treated cells for defects in gross cellular morphology by phase-contrast microscopy. We found that the majority of suramin-treated cells became enlarged and distorted (see below). We also
looked for the ‘BigEye’ phenotype, which is associated with an endocytosis-defect and observed following treatment with the N-myristoyltransferase inhibitor DDD85646 [30], however this phenotype was not seen.

**Melarsoprol inhibits mitosis and suramin inhibits cytokinesis**

Arguably the simplest and most widely used fluorescent-staining method for *T. brucei* is DAPI-staining of DNA followed by microscopy. This is particularly informative for *T. brucei* because cells in which the single mitochondrial genome, or kinetoplast, has segregated are easily visualised and scored, alongside the unsegregated or segregated nuclear genome [31]. We, therefore, examined DAPI-stained cells by microscopy following drug-exposure. Cells were scored according to the number of nuclei (n) and kinetoplasts (k). In non-treated cells (Fig 2A, NT), we found that ~80% of cells displayed a 1n1k pattern (primarily G1 + S-phase), ~15% of cells were 1n2k (primarily G2) and ~5% of cells were 2n2k (post-mitosis). We exercised some caution when analysing these data for drug-treated cells, and focused on only robust phenotypes that preceded or were coincident with loss-of-viability. The analysis revealed a major increase in the proportion of cells with more than two nuclei following suramin treatment (79%), while efornithine treatment also yielded an appreciable increase, with 11% of cells having more than two nuclei (Fig 2A, yellow bars). In addition, we noted ~5% of cells lacking a kinetoplast (0k) following pentamidine treatment (Fig 2A, orange bar, see below). This loss of kinetoplast DNA is consistent with previous observations [28].

DNA staining followed by flow cytometry allows the rapid analysis of large numbers of cells and can reveal relative cellular (primarily nuclear) DNA-content. Accordingly, we next
examined propidium iodide stained cells by flow cytometry following drug-exposure. Untreated cells showed the characteristic profile, with a G2/M population that was approximately half the magnitude of the G1 population (Fig 2B, top-left and red profiles). In this assay, both nifurtimox-treated and pentamidine-treated cells conformed to the profile observed for untreated cells. In contrast, and consistent with the microscopy analysis above, we observed >70% of cells with >2n DNA content following suramin treatment; eflornithine treatment also yielded an appreciable increase in this category (Fig 2B, blue profiles). Only melarsoprol treatment yielded a second, distinct and notable perturbation using this assay; the G2/M population increased from 51% to 83%, relative to the G1 population (Fig 2B, blue profile). Since we had not scored an increase in the proportion of 2n cells by microscopy following melarsoprol-treatment, this particular flow-cytometry profile indicated an increase in cells with a replicated but unsegregated nuclear genome. Thus, DNA-staining with microscopy and flow cytometry suggested that suramin inhibited cytokinesis and that melarsoprol inhibited mitosis (see below).

DNA replication in kinetoplasts and DNA damage in nuclei

The TUNEL (Terminal deoxynucleotidyl transferase dUTP Nick End Labelling) assay allows the fluorescent labelling and detection of blunt DNA ends, following programmed cell-death
(PCD) for example; notably, conventional PCD is not thought to operate in trypanosomatids [32]. Using this assay, TUNEL-signals were not readily detected in trypanosome nuclei. In contrast, and as previously reported [33], we observed robust signals associated with kineto-plasts (Fig 3A). We found approximately 25% of control cells to be TUNEL-positive (Fig 3A). Eflornithine, nifurtimox and melarsoprol-treatment did not significantly alter the proportion of cells with detectable TUNEL-signals when compared to cells that had not been exposed to drug (Fig 3A), but the proportions of TUNEL-positive cells were significantly reduced following pentamidine or suramin-treatment (Fig 3A). This was likely due to loss of kinetoplast DNA following pentamidine-treatment (see above) and may have been due to limited repeated rounds of kinetoplast DNA replication in multi-nucleated cells following suramin-treatment (see below).

TUNEL signals were found to be cell cycle dependent (Fig 3B), consistent with the high concentration of transient nicked DNA ends expected to be present during the replication of thousands of minicircles [34]. Indeed, the majority (91%) of elongated kinetoplasts (in G1-phase cells) and a substantial proportion (22%) of segregated kinetoplasts (in G0 cells) were TUNEL-positive, while we observed very few TUNEL-positive kinetoplasts in G0 or post-mitotic cells (Fig 3C). The TUNEL-signals were consistently observed at opposite poles of extended kineto-plasts and, when present, on both segregated kinetoplasts. Notably, the appearance of kinetoplast-associated TUNEL-signals remained synchronised even in those suramin-treated cells with four kinetoplasts; all four were either negative or positive in each cell (Fig 3D). Thus, TUNEL revealed those cells that are progressing through kinetoplast S-phase and indicated continued synchronisation, even in cells with four kinetoplasts.

We previously identified trypanosome γH2A, a modified histone H2A that is phosphorylated at the C-terminus and that accumulates at sites of nuclear DNA double-strand breaks [35]. To assess nuclear DNA damage in drug-treated cells, we used a γH2A antibody in an immunofluorescence assay; methyl methanesulfonate (MMS) is a radiomimetic DNA-damaging agent and was included as a positive control (Fig 3E). We found no significant differences in the proportion of cells with nuclear γH2A foci compared to untreated cells (Fig 3E), suggesting that none of the current drugs kill trypanosomes by forming double-strand breaks in nuclear DNA. Notably, the nitro pro-drugs, nifurtimox and fexinidazole, although found to be mutagenic by Ames test (Salmonella typhimurium based assay), are not thought to be genotoxic to mammalian cells [36,37].

Both nifurtimox and pentamidine disrupt mitochondrial membrane potential

MitoTracker fluorescence staining is dependent upon mitochondrial membrane potential. We treated trypanosomes with antitypanosomal drugs and scored cells by microscopy for an extended MitoTracker signal, as observed in non-treated cells (Fig 4A, NT panels). Significantly fewer cells scored positive for extended signals following either nifurtimox or pentamidine-treatment, compared to non-treated cells (Fig 4A). There were also qualitative differences in signals resulting from drug treatments; whereas pentamidine eliminated the detectable signal, nifurtimox-treatment produced an intense and discreet signal adjacent to the kinetoplast (Fig 4A). Notably, mitochondrial membrane potential was maintained following suramin-treatment (Fig 4A), despite the gross morphological perturbations observed in these cells.

LysoTracker is highly selective for acidic organelles. We treated trypanosomes with antitypanosomal drugs and scored cells for LysoTracker signals by microscopy. Non-treated cells displayed a single signal between the nucleus and kinetoplast (~60%), as expected for the trypanosome lysosome (Fig 4B, NT panels). Melarsoprol substantially reduced the proportion of
LysoTracker-positive cells (Fig 4B), but this failed to achieve statistical significance. In the case of suramin, which is known to accumulate in trypanosomes through receptor-mediated endocytosis [14], acidification of the lysosomal compartment does not appear to be perturbed (Fig 4B). The variability we observe in this assay suggests either that additional replicates will be desirable in future, or that this particular assay will be of value only when major lysosomal perturbation occurs.

Pentamidine induces progressive loss of kinetoplast DNA

Using the DAPI, TUNEL and MitoTracker assays following pentamidine-treatment, we observed kinetoplast-loss, a reduced proportion of positive cells and a loss of mitochondrial membrane potential, respectively. To quantify these effects, we scored each phenotype
following 12, 24, and 48 h of drug-exposure (Fig 5A–5C). These analyses revealed a sharp increase in kinetoplast-negative cells in the 48-h DAPI-stained population (Fig 5A) and a progressive decline in TUNEL-positive (Fig 5B) and MitoTracker-positive cells (Fig 5C) at each time-point.

DAPI-stained cells appeared to reveal progressively diminished kinetoplast DNA rather than loss in one step. For a quantitative and objective assessment of kinetoplast DNA-staining intensity, we adapted an ImageJ-based approach [31]; see Materials and methods. ImageJ efficiently identified nuclei and kinetoplasts in untreated cells (Fig 5D, red and green, respectively in the upper panel), but failed to identify very low-intensity kinetoplasts in pentamidine-treated cells (Fig 5D, open green circle in the lower panel). A quantitative analysis indicated that the kinetoplasts that are still detected following pentamidine-treatment display reduced surface area and signal intensity relative to the control population; values are expressed relative to nuclei in the same cell (Fig 5D). These results confirm progressive loss of kinetoplast DNA induced by pentamidine.

**Nifurtimox induces a specific reduction in mitochondrial protein abundance**

Nifurtimox-treatment produced an intense and discreet MitoTracker signal adjacent to the kinetoplast (Fig 4A). To explore this effect further, we stained the nuclear-encoded F1β-subunit of the mitochondrial ATP-synthase (Tb927.3.1380) in drug-treated and MitoTracker-stained cells and examined these cells by microscopy. The ATP-synthase signal was largely coincident with the extended MitoTracker signal in control cells (Fig 6A, NT panels) and was
also coincident with the focal MitoTracker signal in nifurtimox-treated cells (Fig 6A, Nif panels), possibly indicating a structural defect in mitochondria in the latter cells. We next assessed F1β-subunit expression by protein blotting of whole-cell extracts, which revealed a substantial and specific reduction in abundance following nifurtimox-treatment (Fig 6B). Depletion of the ATP-synthase component may reflect a more widespread depletion of mitochondrial proteins, consistent with activation of this pro-drug by a mitochondrial NTR [14,25,26]. Using the same assays, pentamidine-treated cells displayed a diffuse and cytosolic, rather than mitochondrial, ATP-synthase signal (Fig 6A, Pen panels). In this case, protein import into mitochondria [38] may be defective as a result of loss of mitochondrial membrane potential, as indicated by the diminished MitoTracker signal (Fig 6A, Pen panels). Consistent with this hypothesis, the total cellular F1β signal detected by protein blotting remained constant following pentamidine treatment (Fig 6B).

Melarsoprol inhibits mitosis by a mechanism that is suppressed by multiple kinases

DNA staining followed by microscopy or flow cytometry suggested that melarsoprol inhibited mitosis. Indeed, a closer inspection of DAPI-stained cells revealed a sub-set (>10%) with “conjoined” nuclei (Fig 7; top panels, double-arrowheads). For an objective assessment of nuclear DNA-staining intensity in these cells, we used the quantitative ImageJ-based approach; see Materials and methods. In this case, nuclei were compared to kinetoplasts in ’1n2k’ cells,
revealing both increased nuclear surface area and signal intensity following melarsoprol-treatment (Fig 7). These quantitative results confirmed the mitotic defect resulting from melarsoprol treatment.

Cytology-based profiling may be combined with orthogonal approaches to probe antitrypanosomal compound MoA. We have found high-throughput genetic screening to be particularly informative [13,14]. A prior RNA interference (RNAi) Target Sequencing (RIT-seq) screen revealed a highly significant ($P = 2.3 \times 10^{-9}$) over-representation of kinases, comprising three hits among the top seven in this screen; these were a putative mitogen-activated protein kinase (MAPK11, Tb927.10.12040), a putative MAPK kinase (MKK4, Tb927.8.5950) and a putative MAPK kinase kinase (STE11, Tb927.10.1910) [14]. It is also notable that trypanosome CDC14 (Tb927.11.12430) was a hit in this screen, since human Cdc14 stabilises Wee1, a key

---

**Fig 6. Nifurtimox induces a specific reduction in mitochondrial protein abundance.** (A) The microscopy images show the Mitotracker signals and F1β mitochondrial ATP-synthase subunit following nifurtimox or pentamidine treatment. Scale bar, 5 μm. (B) Protein blotting to detect the F1β mitochondrial ATP-synthase subunit following nifurtimox or pentamidine treatment; predicted size, 55.8 kDa.

https://doi.org/10.1371/journal.pntd.0006980.g006
kinase that inhibits mitosis [39]. Thus, knockdowns that promote mitosis may partially counteract the inhibitory effects of melarsoprol, but the RIT-seq screening hits noted above have not previously been independently validated nor further characterised. To explore our

![Fig 7. Quantitative analysis of the melarsoprol-induced mitotic defect.](https://doi.org/10.1371/journal.pntd.0006980.g007)

(A) ImageJ analysis. Raw images (left hand panels) and ImageJ outputs (right hand panels) demonstrating conjoined nuclei (red arrowheads) after melarsoprol treatment. (B) DNA content of nuclei in melarsoprol (Mel) treated and non-treated (NT) cells is plotted. Ratio of area and signal (area multiplied by average intensity) of nuclei to average area and signal of kinetoplasts in '1n2k' cells. Error bars, SD; red lines, averages; ***, P < 0.001 from Students t-test.
hypothesis, we further characterised these kinases. All three were expressed with a C-terminal 12-myc epitope tag and the tagged proteins were all found to localise to the trypanosome cytosol (Fig 8A). Since RIT-seq screening fails to yield clonal knockdown strains [14], we assembled pairs of independent knockdown strains for two of the kinases (Tb927.10.12040 and Tb927.8.5950). Both knockdowns, confirmed by monitoring the epitope-tagged proteins (Fig 8B), reproducibly and significantly \( P < 0.0001 \) increased melarsoprol EC\(_{50}\) by 1.7 +/- 0.07 fold and 1.5 +/- 0.01 fold, respectively (Fig 8C), as predicted by the RIT-seq screen [14]. Finally, we determined whether knockdown alleviated the melarsoprol-induced, conjoined-nuclei phenotype and found that this was indeed the case for both kinases (Fig 8D). Thus, the melarsoprol-induced mitotic defect is kinase-dependent.

**Discussion**

Cytocidal or cytostatic compounds identified using phenotypic approaches may target proteins, nucleic acids, membranes or other metabolites. They may also exhibit polypharmacology, killing cells by perturbing multiple pathways. Even compounds developed as target-based therapies may kill trypanosomes by ‘off-target’ mechanisms. Determining mechanism of action remains a major challenge for these drugs and compounds and an improved understanding of how they kill parasites could present new opportunities in terms of developing more potent compounds, delivering compounds to their targets more effectively or devising combination therapies that minimise the likelihood of resistance. Eflornithine kills trypanosomes by inhibiting ornithine decarboxylase but the mode-of-action of the other four current antitrypanosomal drugs is not known. Our studies indicate that cytology-based profiling can provide a rapid and effective means to yield insight into drug mode-of-action and we now present additional insights into the mode-of-action for all current drugs used to treat human African trypanosomiasis.

Suramin was found to produce cells with more than two nuclei, indicating a defect in cytokinesis with continued mitosis. Multi-nucleated cells were still stained by MitoTracker, indicating that this organelle retained membrane potential. DAPI-staining and TUNEL (terminal dUTP nick end labelling) assays indicated that nuclear:nuclear and nuclear:kinetoplast replication remained synchronised in these cells. Indeed, although the TUNEL assay failed to reveal any nuclear DNA damage induced by the drugs used here, it did provide an excellent marker for the kinetoplast replication cycle, producing robust signals consistent with the presence of DNA-ends at antipodal sites on the kinetoplast during minicircle DNA replication [34]. In this regard, TUNEL provides a useful marker for kinetoplast S-phase.

Pentamidine is a DNA-binding drug [21] that collapses trypanosome mitochondrial membrane potential [22] and induces loss of kinetoplast DNA [28]. Data from *Saccharomyces cerevisiae* indicated pentamidine accumulation in the mitochondrion but also inhibition of translation in these cells [40]. In addition, metabolomic studies indicated that pentamidine is unlikely to act through the inhibition of any specific metabolic pathways [41]. We find that pentamidine-induced loss of kinetoplast DNA is progressive, suggesting progressive loss of maxi- and minicircles; the latter are present in thousands of copies per kinetoplast [34]. Kinetoplast DNA loss is revealed by both DAPI-staining and TUNEL-assay. Loss of kinetoplast DNA is expected to disrupt membrane-potential since the A6-subunit of the ATP-synthase, required to maintain this potential, is encoded by kinetoplast DNA [42]. Thus, we suggest that kinetoplast DNA is indeed a primary target for pentamidine, involving inhibition of mitochondrial type II topoisomerase action, as previously suggested [43]. What remains unclear is whether loss of mitochondrial membrane-potential is solely a consequence of the kinetoplast defect or whether this reflects an independent response to pentamidine.
Nifurtimox is a pro-drug that is activated by a mitochondrial NTR [26], but it is unknown whether the toxic metabolite(s) access(es) targets outside the mitochondrion, or whether parasite killing is primarily due to disruption of mitochondrial functions. We found that nifurtimox, like pentamidine, also disrupted the MitoTracker signal. Kinetoplast defects were not observed, however, and the MitoTracker staining pattern was distinct to that seen with pentamidine. Nifurtimox also induced loss of a nuclear-encoded ATP-synthase subunit, while data from pentamidine-treated cells indicated that ATP-synthase was still expressed, but not imported, when membrane potential was perturbed. Thus, we suggest severe disruption of mitochondrial structure and function by nifurtimox, consistent with damage to targets in the organelle where the drug is activated. Fexinidazole is another nitro pro-drug, currently in clinical trials, that is also activated by mitochondrial NTR [25]. These drugs may act through similar antitrypanosomal mechanisms.

Melarsoprol forms potentially toxic adducts with trypanothione [19], and we now show that this drug increases the proportion of cells with a replicated but unsegregated nuclear genome. This indicates a defect in mitosis. The identification of multiple putative kinases in a loss-of-function screen for melarsoprol-resistance suggested a role for a signalling cascade in melarsoprol susceptibility [14]. The current findings led us to consider a more specific role for these putative kinases in the control of mitosis. Indeed, these proteins are putative MAPK, MAPKK and MAPKKKs and our results now indicate that the mitotic defect is less
pronounced when the putative MAPK (Tb927.10.12040) and MAPKK (Tb927.8.5950) are depleted. We suggest that these kinases negatively control mitosis, as part of normal quality control following DNA replication. Bypass of this surveillance could allow cells to continue to grow, possibly accumulating, but tolerating, melarsoprol-induced (oxidative) damage. Thus, knockdowns that promote mitosis may partially counteract the inhibitory effects of melarsoprol.

Arsenicals are used to treat leukemia but are also themselves mutagens. There is indeed evidence that arsenic induces DNA damage in yeast [44]. Notably, the MoA in yeast involves activation of a MAP kinase pathway [45] and this also appears to be the case in mammalian cells [46], where mitotic arrest occurs as a result of induction of a mitotic spindle checkpoint [47]. We did not detect any evidence for nuclear DNA damage in *T. brucei* following melarsoprol treatment but, as detailed above, did find a melarsoprol-dependent and kinase-dependent mitotic defect. Thus, arsenical MoA may operate through a common kinase signalling cascade leading to mitotic arrest in both trypanosomes and mammalian cells. Notably, like the Myt1 kinase, which phosphorylates Cdc2 and controls mitosis in *Xenopus* [48], Tb927.10.1910 has a putative transmembrane domain; Tb927.10.1910 also has a putative guanylate cyclase domain. These findings illustrate how cytology and genetic approaches can converge to yield insights into drug MoA in trypanosomes. In this case, we propose a common MoA for arsenicals in human cells and in trypanosomes.

Cytology-based approaches can provide rapid and cost-effective methods for quantitative profiling of cellular responses to drugs. The drugs can also be considered as chemical probes for exploring parasite biology. Taking a systematic cytology-based approach with antitrypanosomal drugs of uncertain MoA, our findings indicate target organelles and structures for pentamidine, nifurtimox and melarsoprol; the kinetoplast, the mitochondrion and the nucleus, respectively. Further analysis, guided by the primary assays, indicated destruction of mitochondrial ATP-synthase by nifurtimox and a mitotic defect induced by melarsoprol. These assays should also provide novel insights into MoA when applied to cells treated with other antitrypanosomal compounds, including those with known primary targets. Common profiles will allow compounds to be clustered based on their primary MoA. New assays and bespoke assays can be incorporated as appropriate and these may be guided by outputs from orthogonal genetic, proteomic, metabolomic or computational approaches. The approach may also be usefully applied to the other parasitic trypanosomatids, *T. cruzi* and *Leishmania*. These and other approaches should reveal those particularly susceptible pathways that can be prioritised and targeted by antitrypanosomal therapies.

Materials and methods

Strains and drugs

Lister 427 derived *T. brucei* (clone 221a) bloodstream form cells were grown in HMI-11 in the presence of antitrypanosomal drugs. Cultures were initiated at $2 \times 10^5$ cells.ml$^{-1}$ and incubated at 37°C in a humidified 5% CO$_2$ atmosphere. The drugs were applied at five times the EC$_{50}$, as determined using a standard AlamarBlue assay [49]; for EC$_{50}$ determination, drug exposure was for 66–67 h and AlamarBlue incubation was for 5–6 h. Plates were read on an Infinite 200 Pro plate-reader (Tecan). The EC$_{50}$ values of the antitrypanosomal drugs used were: Eflornithine 15 μM; Melarsoprol 7 nM; Nifurtimox 2.6 μM; Pentamidine 2.5 nM; Suramin 27 nM. Methyl methanesulfonate (MMS, Sigma) was used at 0.0003%. To monitor cumulative trypanosome growth, cultures were grown in the presence of drug, with four technical replicates of cell density counted at 6, 9, 24, 48, 72 and 96 h. Cultures were diluted with fresh media containing the appropriate drug, such that cell density never exceeded $2 \times 10^6$ cells.ml$^{-1}$. All
tagging and RNAi constructs were transfected into 2T1 *T. brucei* cells [50]. RNAi was induced with tetracycline (1 μg/ml) for three days prior to initiating EC50 determination.

**Microscopy**

Cells were grown in the presence of drug at 5 x EC50 for 24 h, unless stated otherwise. Cells were then fixed in 2% v/v paraformaldehyde for 30 min at 4°C before being washed three times in PBS. Fixed cells were dried onto slides before staining with antibodies (outlined below). Slides were washed in PBS and mounted in Vectashield containing DAPI (Vector Laboratories); 4, 6-diamidino-2-phenylindole. Scoring of phenotypes was carried out by counting 100 cells per condition, and by two of us, with the data combined. For immunofluorescence analysis (IFA), cells dried onto slides were permeabilised in 0.5% Triton X100 / PBS for 20 min and washed three times in PBS before blocking in 50% foetal bovine serum FBS / PBS. Primary antibody (α-γH2A) [35] was diluted 1:250 and applied for 1 h, slides were washed three times in PBS, and secondary antibody (fluorescein-conjugated goat anti-rabbit) was diluted 1:100 and then applied for 1 h. Antibodies were applied in 3% FBS / PBS. The F1β-subunit of the mitochondrial ATP-synthase was similarly detected using a polyclonal rabbit antiserum directed against the *Crithidia fasciculata* ATP synthase (1:500), which cross-reacts with the *T. brucei* orthologue [51,52]. All phase and epifluorescence images were captured on an Eclipse E600 microscope (Nikon) using a Coolsnap FX (Photometrics) charged coupled device camera and processed in Metamorph 5.4 (Photometrics).

**MitoTracker assay**

MitoTrackerRed (Invitrogen) was added to cultures at 100 nM. Cultures were incubated for 5 min under standard conditions before parasites were harvested by centrifugation at 1000 x g for 10 min before fixing as outlined above.

**LysoTracker assay**

LysoTracker (Invitrogen) was added to cultures at 50 nM. Cultures were incubated under standard conditions for 1 h before parasites were harvested by centrifugation at 1000 x g for 10 min before fixing as outlined above.

**TUNEL assay**

Cells on slides were fixed, dried and permeabilised as described above for IFA. Reaction mix from the ‘In Situ Cell Death Detection Kit (fluorescein)’ (Roche) was applied to cells for 1 h as per the manufacturer’s instructions.

**Flow cytometry**

Cells were harvested and washed in ice cold PBS and resuspended in 300 μl PBS before the addition of 700 μl of methanol and stored at 4°C for 12 h. Cells were then harvested at 400 x g for 10 min at 4°C and resuspended in 1 ml PBS. 10 μg/ml RNase A and 10 μg/ml propidium iodide was added to each sample and incubated at 37°C for 45 min in the dark. Analysis was performed on an LSRII flow cytometer (BD Biosciences), and data analysis was conducted in FlowJo (Tree Star).

**ImageJ analysis**

All images of DAPI fluorescence were captured at 40 ms exposure time for consistency and to avoid overexposure. They were analysed using an ImageJ plug-in [31] modified to enable cell
cycle analysis from DAPI and phase contrast images. DAPI alone was suitable for the identification of nuclei and kinetoplasts, since kinetoplasts do not generally overlap with nuclear DNA signals in bloodstream form *T. brucei*. As in the original ImageJ plug-in, two kinetoplasts are counted only when no longer linked by pixels with signal. A subset of the original macros were retained and modified, as necessary: Measure K/N Signal, Cell Analysis, K/N Count Summary, and Save Analysis. First, the *Measure K/N Signal* tool thresholds images using built-in ImageJ functions, and extracts object area values from DAPI images. Next, the script applies the K-means clustering algorithm [31] to separate kinetoplasts and nuclei into respective clusters, returning values for the maximum kinetoplast area and minimum nucleus area. These values are then passed to the *Cell Analysis* tool which finds objects in phase images, creates binary copies of the phase and DAPI image and identifies kinetoplasts and nuclei, counting how many lie within each cell. *K/N Count Summary* and *Save Analysis* tools function identically to the original macros described in [31]. Macro scripts are available on request.

### Plasmid construction

For tagging native Tb927.8.5950, Tb927.10.12040 and Tb927.10.1910 alleles with 12-myc epitope tags at the C-terminus, we used the following primer-pairs, to amplify 893, 1038 and 769 bp fragments, respectively: 5950MF (GATC*AAGCTT*GATCCATGTGT AGTTGAC) and 5950MR (GATCTCTAGAGGATACTGGTGAAACC ATC); 12040MF (GATC*AAGCTTGGCA CACTTCCACCAGAT) and 12040MR (GATCTCTAGACCTCAACGGAACCACATATT); 1910MF (GATCAAGCTTGGGTATCTAGCATGGA) and 1910MR (GATCTCTAGAA AGGAAAAAGT). These primer-pairs incorporate HindIII and XbaI sites, respectively (italics). The resulting fragments were cloned in the pNATx12MYC construct [53]. The resulting pNAT5950-12myc, pNAT12040-12myc and pNAT1910-12myc constructs were linearized by digestion with BstZ171, EcoRV and EcoRV prior to transfection, respectively. For knockdown of Tb927.8.5950 or Tb927.10.12040 using RNA interference, we used the following primer-pairs, respectively: 5950RF2 (GATC*TCTAGAGGATCC AAACGACCCA AGTTGGAGAG) and 5950RR2 (GATC*GGGCCCGGTACC GCTTCCAGCG TCCATGTATT); 12040RF2 (GATC*TCTAGAGGATCC ATTCTTGGTGAGTTGCTGGG ) and 12040RR2 (GATC*GGGCCCGGTACC ACTCTCATCACACCAGCC). These primer-pairs incorporate XbaI / BamHI and ApaI / KpnI sites, respectively (italics). The resulting fragments were cloned in the pRPaRNAi construct [53]. The resulting pRPa5950-RNAi and pRPa12040-RNAi constructs were linearized by digestion with Ascl prior to transfection.

### Protein blotting

Total cell extracts were separated on SDS-polyacrylamide gels and subjected to standard western blotting analysis. Duplicate gels were generated and one was stained with Coomassie and the other was used to produce the nitrocellulose blot. Blots were blocked in 5% milk in TBST and washed were performed in TBST (0.05% Tween). Blots were then probed with mouse α-c-Myc primary antibody (1:5000; 9E10, Source Biosciences) or the ATP synthase primary antibody (1:500). Following incubation with the appropriate secondary antibodies (1:2000; Pierce), membrane was washed and visualised using the Amersham enhanced chemiluminescence (ECL) detection system (GE Healthcare Life Sciences) according to the manufacturer instructions.

### Acknowledgments

We thank Philippa Radley for assistance with assembly of tagging constructs, Richard Wheeler (Uni. of Oxford) for advice on ImageJ analysis and Achim Schnaufer (Uni. of Edinburgh) for the ATP-synthase antibody.
Author Contributions
Conceptualization: James A. Thomas, David Horn.
Formal analysis: James A. Thomas, David Horn.
Funding acquisition: David Horn.
Investigation: James A. Thomas, Nicola Baker, Sebastian Hutchinson, Caia Dominicus, Anna Trenaman, Lucy Glover, Sam Alsford.
Supervision: David Horn.
Writing – original draft: James A. Thomas, David Horn.
Writing – review & editing: James A. Thomas, David Horn.

References
1. Field M, Horn D, Fairlamb A, Ferguson M, Gray D, et al. (2017) Antitrypanosomal Drug Discovery: An ongoing challenge and a continuing need. Nature Reviews Microbiology 15: 217–231. https://doi.org/10.1038/nrmicro.2016.193 PMID: 28239154
2. Fairlamb AH, Gow NA, Matthews KR, Waters AP (2016) Drug resistance in eukaryotic microorganisms. Nature microbiology 1: 16092. https://doi.org/10.1038/nmicrobiol.2016.92 PMID: 27572976
3. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374: 56–64. https://doi.org/10.1016/S0140-6736(09)61117-X PMID: 19559476
4. Kuepfer I, Schmid C, Allain M, Edielu A, Haary EP, et al. (2012) Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness. PLoS neglected tropical diseases 6: e1685. https://doi.org/10.1371/journal.pntd.0001685 PMID: 22970324
5. Baker N, Glover L, Munday JC, Aguinaga Andres D, Barrett MP, et al. (2012) Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proceedings of the National Academy of Sciences of the United States of America 109: 10996–11001. https://doi.org/10.1073/pnas.1202885109 PMID: 22711816
6. Fairlamb AH, Horn D (2018) Melarsoprol resistance in African trypanosomiasis. Trends in parasitology pii: S1471–4922.
7. Graf FE, Ludin P, Wenzler T, Kaiser M, Brun R, et al. (2013) Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol. PLoS neglected tropical diseases 7: e2475. https://doi.org/10.1371/journal.pntd.0002475 PMID: 24130910
8. Iten M, Mett H, Evans A, Enyaru JC, Brun R, et al. (1997) Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrobial agents and chemotherapy 41: 1922–1925. PMID: 9303985
9. Jacobs RT, Nare B, Wiring SA, Orr MD, Chen D, et al. (2011) SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS neglected tropical diseases 5: e1151. https://doi.org/10.1371/journal.pntd.0001151 PMID: 21738803
10. Mesu V, Kallonji WM, Bardonneau C, Mordt OV, Blesson S, et al. (2018) Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet 391: 144–154. https://doi.org/10.1016/S0140-6736(17)32758-7 PMID: 29113731
11. Vincent IM, Creek D, Watson DG, Kamleh MA, Woods DJ, et al. (2010) A molecular mechanism for eflorenthine resistance in African trypanosomes. PLoS pathogens 6: e1001204. https://doi.org/10.1371/journal.ppat.1001204 PMID: 21124924
12. Bacchi CJ, Nathan HC, Hutmier SH, McCann PP, Sjoerdsma A (1980) Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210: 332–334. PMID: 6775372
13. Wall RJ, Rico E, Lukac I, Zuccotto F, Elg S, et al. (2018) Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proceedings of the National Academy of Sciences of the United States of America 115: 9616–9621. https://doi.org/10.1073/pnas.1807915115 PMID: 30185555
14. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, et al. (2012) High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482: 232–236. https://doi.org/10.1038/nature10771 PMID: 22278056
15. Wiedemar N, Graf FE, Zwyer M, Ndomba E, Kunz Renggli C, et al. (2018) Beyond immune escape: a variant surface glycoprotein causes suramin resistance in *Trypanosoma brucei*. Molecular microbiology 107: 57–67. https://doi.org/10.1111/mmi.13854 PMID: 28963732

16. Macedo JP, Currier RB, Wirndam C, Horn D, Alsford S, et al. (2017) Ornithine uptake and the modulation of drug sensitivity in *Trypanosoma brucei*. FASEB journal 31: 4649–4660. https://doi.org/10.1096/fj.201700311R PMID: 28679527

17. Morgan HP, McNea IW, Nowicki MW, Zhong W, Michaels PA, et al. (2011) The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site. The Journal of biological chemistry 286: 31232–31240. https://doi.org/10.1074/jbc.M110.212613 PMID: 21738389

18. Maser P, Sutterlin C, Krauli A, Kaminsky R (1999) A nucleoside transporter from *Trypanosoma brucei* involved in drug resistance. Science 285: 242–244. PMID: 10385598

19. Fairlamb AH, Henderson GB, Cerami A (1989) Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proceedings of the National Academy of Sciences of the United States of America 86: 2607–2611. PMID: 2704738

20. Song J, Baker N, Rothert M, Henke B, Jeacock L, et al. (2016) Pentamidine is not a permeant but a nanomolar inhibitor of the *Trypanosoma brucei* aquaglyceroporin-2. PLoS pathogens 12: e1005436. https://doi.org/10.1371/journal.ppat.1005436 PMID: 26828608

21. Wilson WD, Tanious FA, Mathis A, Tevis D, Hall JE, et al. (2008) Antiparasitic compounds that target DNA. Biochimie 90: 999–1014. https://doi.org/10.1016/j.bioch.2008.02.017 PMID: 18343228

22. Lanteri CA, Tidwell RR, Meshnick SR (2008) The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of *Trypanosoma brucei*. Antimicrobial agents and chemotherapy 52: 875–882. https://doi.org/10.1128/AAC.00642-07 PMID: 18086841

23. Damper D, Patton CL (1976) Pentamidine transport and sensitivity in brucei-group trypanosomes. The Journal of protozoology 23: 349–356. PMID: 6797

24. Gould MK, Schnaufer A (2014) Independence from kinetoplast DNA maintenance and expression is associated with multidrug resistance in *Trypanosoma brucei* in vitro. Antimicrobial agents and chemotherapy 58: 2925–2928. https://doi.org/10.1128/AAC.00122-14 PMID: 24550326

25. Sokolova AY, Wylie S, Patterson S, Oza SL, Read KD, et al. (2010) Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrobial agents and chemotherapy 54: 2893–2900. https://doi.org/10.1128/AAC.00332-10 PMID: 20439607

26. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proceedings of the National Academy of Sciences of the United States of America 105: 5022–5027. https://doi.org/10.1073/pnas.0711014105 PMID: 18367671

27. Noneuje P, Burkart M, Pogliano K, Pogliano J (2013) Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. Proceedings of the National Academy of Sciences of the United States of America 110: 16169–16174. https://doi.org/10.1073/pnas.1311066110 PMID: 24046367

28. Wirthen C, Jensen BC, Parsons M (2010) Diverse effects on mitochondrial and nuclear functions elicited by drugs and genetic knockdowns in bloodstream stage *Trypanosoma brucei*. PLoS Negl Trop Dis 4: e678. https://doi.org/10.1371/journal.pntd.0000678 PMID: 20454560

29. De Rycker M, O’Neill S, Yoshi D, Campbell L, Gray DW, et al. (2012) A static-cidal assay for *Trypanosoma brucei* to aid hit prioritisation for progression into drug discovery programmes. PLoS neglected tropical diseases 6: e1932. https://doi.org/10.1371/journal.pntd.0001932 PMID: 23209868

30. Frearson JA, Brand S, McElroy SP, Cleghorn LA, Smid O, et al. (2010) N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464: 728–732. https://doi.org/10.1038/nature08893 PMID: 20360736

31. Wheeler RJ, Gull K, Gluenz E (2012) Detailed interrogation of trypanosome cell biology via differential organelle staining and automated image analysis. BMC Biol 10: 1. https://doi.org/10.1186/1741-7007-10-1 PMID: 22214525

32. Proto WR, Coombs GH, Mottram JC (2013) Cell death in parasitic protozoa: regulated or incidental? Nature reviews Microbiology 11: 58–66. https://doi.org/10.1038/nmicrobiol.2929 PMID: 23202528

33. Guilbride DL, Englund PT (1998) The replication mechanism of kinetoplast DNA networks in several trypanosomatid species. Journal of cell science 111 (Pt 6): 675–679.

34. Jensen RE, Englund PT (2012) Network news: the replication of kinetoplast DNA. Annu Rev Microbiol 66: 473–491. https://doi.org/10.1146/annurev-micro-092611-150057 PMID: 22994497

35. Glover L, Horn D (2012) Trypanosomal histone γH2A and the DNA damage response. Mol Biochem Parasitol 183: 78–83. https://doi.org/10.1016/j.molbiopara.2012.01.008 PMID: 22353557
36. Ferreira RC, Ferreira LC (1986) Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Brazilian journal of medical and biological research 19: 19–25. PMID: 3542090

37. Torreele E, Bourdin Trunz B, Tweetz D, Kaiser M, Brun R, et al. (2010) Fexinidazole—a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS neglected tropical diseases 4: e923. https://doi.org/10.1371/journal.pntd.0000923 PMID: 21200426

38. Harsman A, Schneider A (2017) Mitochondrial protein import in trypanosomes: Expect the unexpected. Traffic 18: 96–109. https://doi.org/10.1111/tra.12463 PMID: 27976830

39. Ovejero S, Ayala P, Bueno A, Sacristan MP (2012) Human Cdc14A regulates Wee1 stability by countering CDK-mediated phosphorylation. Molecular biology of the cell 23: 4515–4525. https://doi.org/10.1091/mbc.E12-04-0260 PMID: 23051732

40. Sun T, Zhang Y (2008) Pentamidine binds to tRNA through non-specific hydrophobic interactions and inhibits aminoacylation and translation. Nucleic acids research 36: 1654–1664. https://doi.org/10.1093/nar/gkm1180 PMID: 18263620

41. Creek DJ, Nijagal B, Kim DH, Rojas F, Matthews KR, et al. (2013) Metabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei. Antimicrobial agents and chemotherapy 57: 2768–2779. https://doi.org/10.1128/AAC.00444-13 PMID: 23571546

42. Schnaufer A, Domingo GJ, Stuart K (2002) Natural and induced dyskinetoplastic trypanosomatids: how to live without mitochondrial DNA. International journal for parasitology 32: 1071–1084. PMID: 12117490

43. Shapiro TA, Englund PT (1990) Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proceedings of the National Academy of Sciences of the United States of America 87: 950–954. PMID: 2153980

44. Litwin I, Bocer T, Dziadkowiec D, Wysocki R (2013) Oxidative stress and replication-independent DNA breakage induced by arsenic in Saccharomyces cerevisiae. PLoS genetics 9: e1003640. https://doi.org/10.1371/journal.pgen.1003640 PMID: 23935510

45. Lee J, Levin DE (2018) Intracellular mechanism by which arsenite activates the yeast stress MAPK Hog1. Molecular biology of the cell 29: 1904–1915. https://doi.org/10.1091/mbc.E18-03-0185 PMID: 29846136

46. Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, et al. (2006) Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer research 66: 6763–6771. https://doi.org/10.1158/0008-5472.CAN-05-3699 PMID: 16818652

47. McNeely SC, Taylor BF, States JC (2008) Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent. Toxicology and applied pharmacology 231: 61–67. https://doi.org/10.1016/j.taap.2008.03.020 PMID: 18501396

48. Mueller PR, Coleman TR, Kumagai A, Dunphy WG (1995) Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 270: 86–90. PMID: 7569953

49. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta tropica 68: 139–147. PMID: 9386789

50. Alsford S, Kawahara T, Glover L, Horn D (2005) Tagging a T. brucei RNA locus improves stable transfection efficiency and circumvents inducible expression position effects. Molecular and biochemical parasitology 144: 142–148. https://doi.org/10.1016/j.molbiopara.2005.08.009 PMID: 16182389

51. Pusnik M, Schneider A (2012) A trypanosomal pentatricopeptide repeat protein stabilizes the mitochondrial mRNAs of cytochrome oxidase subunits 1 and 2. Eukaryotic cell 11: 79–87. https://doi.org/10.1128/EC.05213-11 PMID: 22058141

52. Vanhamme L, Perez-Morga D, Marchal C, Speijer D, Lambert L, et al. (1998) Trypanosoma brucei TBRGG1, a mitochondrial oligo(U)-binding protein that co-localizes with an in vitro RNA editing activity. The Journal of biological chemistry 273: 21825–21833. PMID: 9705321

53. Alsford S, Horn D (2008) Single-locus targeting constructs for reliable regulated RNAi and transgene expression in Trypanosoma brucei. Molecular and biochemical parasitology 161: 76–79. https://doi.org/10.1016/j.molbiopara.2008.05.006 PMID: 18588918